Experts #1 Pharma Stock to Start 2024

[View in browser]( [The Spill Logo] Proprietary Data Insights Financial Pros’ Top Drug Manufacturer Stock Searches in the Last Month Rank Ticker Name Searches #1 [LLY]( Eli Lilly 122 #2 [BMY]( Bristol-Myers Squibb 100 #3 [PFE]( Pfizer 77 #4 [GILD]( Gilead Sciences 40 #5 [AMGN]( Amgen 36 #ad [Navigating Market Volatility: The Alt Advantage]( Brought to you by [Weiss Ratings]( [9,530x the last time this happened]( [Weiss Ratings - 9,530x the last time this happened]( The last of three historically bullish crypto events is expected to happen around April 14. It's only the fourth time in crypto history. The last time, in 2020, certain altcoins exploded. Some as high as 531,735% or even a 953,018% gain. Here's what our expert says you should buy before April 14. [A tiny $100 investment would have returned just short of a million dollars.]( Experts #1 Pharma Stock to Start 2024 Every one of us knows someone touched by diabetes, obesity, or Alzheimer's. Combined, Americans spend almost a trillion dollars annually fighting these conditions. No company has benefited more from this than Eli Lilly (LLY). The pharmaceutical giant developed a robust pipeline that includes new treatments for each condition, propelling shares higher by almost 30% in 2024 and over 140% in the past year. Financial experts took notice, searching out the stock more than any other biotech or pharmaceutical company in February. And it was also one of their top searches in 2023. However, their search history has notably gotten more cautious, and we wondered if they feel the stock’s meteoric rise is overcooked. Let’s find out. Eli Lilly’s Business Lilly operates at the intersection of cutting-edge science and compassionate care, delivering various pharmaceutical solutions. Known for its pioneering work in diabetes care, Lilly has expanded its influence across multiple therapeutic areas with a commitment to improving patient outcomes with cutting-edge treatments and a patient-centric approach. The business breaks down by treatment area: - Diabetes (57.6% of total revenues) - A cornerstone of Lilly's portfolio, this segment includes trailblazing injectable and oral medications that significantly improve the lives of those with diabetes and weight loss medication. - Immunology (9.0% of total revenues) - This segment comprises innovative treatments for autoimmune diseases, reflecting Lilly’s dedication to addressing unmet medical needs in chronic inflammatory conditions. - Neuroscience (8.4% of total revenues) - Encompasses medications for psychiatric disorders, neurodegeneration, and pain management. - Oncology (19.5% of total revenues) - This segment delivers targeted therapies reshaping the oncological (cancer) landscape. - Other Products (5.5% of total revenues) - This diverse category includes additional medications and health solutions that further illustrate Lilly’s broad reach in healthcare. Lilly’s focus on diabetes (Mounjaro) and weight loss (Zepound) is expected to pay big dividends. [Update] [Source: Eli Lilly Investor Relations]( Its product portfolio is growing so quickly that management expects revenues to increase 20% in 2024 (29% excluding divestitures). Behind that, Lilly’s $8.1 billion R&D spend has filled its pipeline with a treasure trove of possible treatments. [Pipeline] [Source: Eli Lilly Investor Relations]( Lilly faces a minor patent cliff with Taltz and Truliciy in 2028 and 2027, representing 29% of the company’s 2023 revenues, respectively. However, analysts expect current growth and new product sales to far exceed any decline when those two drugs go generic. Financials [Financials] Source: Stock Analysis Eli Lilly’s growth really took off in 2021, with revenues climbing double digits. Though they faced a minor setback in 2022, management expects sales to increase 20% overall in 2024. Margins have declined slightly as the company focused on launching and rolling out new products. That’s not expected to change in the near future as Lilly continues to focus on building its pipeline. However, free cash flow should return to normal as 2023 divestitures are one-time items. Valuation [Valuation] Source: Seeking Alpha Now, we get to the big question mark - Lilly’s valuation. Compared ti its peers, it’s not in the same universe. Pfizer (PFE) trades at 72.7x, trailing 12-month but 17.3x forward earnings. Lilly is at 131.9x and 63.1x, respectively. In fact, Lilly’s 162.4x cash is over 9x higher than Amgen’s (AMGN). However, Lilly trades at 55.6x forward operating cash flow, which is a bit more reasonable. Growth [Growth] Source: Seeking Alpha Does Lilly’s growth justify its valuation? It’s certainly far ahead of its peers. Bristol Myers Squibb (BMY) expects just 0.25% revenue growth in 2024. Gilead (GILD) is looking at 0.96% for the same period. At least Amgen believes it can hold onto its high single-digit growth. And for the most part, Lilly’s profits have risen proportionally with its revenues. Profitability [Profit] Source: Seeking Alpha At the moment, Lilly’s margins aren’t the best, but they’re still pretty solid. Ideally, its EBIT and EBITDA margins would improve as its new products mature. However, that may be a few years down the road. Our Opinion 6/10 There’s a good argument to be made that Eli Lilly will grow in its valuation within a few years. And its patent protection doesn’t come under fire until 2027. So, +20% growth every year is reasonable. However, the forward cash estimates are a bit generous. For us, this stock would become interesting back down around $600. [-facebook-share]( [-twitter-share]( [-linkedin-share]( [-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D607748?utm_medium=ic-nl&utm_source=116469 ) News & Insights Just Spilled - [Experts Top 5 Oil & Gas Exploration Stocks For February]( - [Master the Art of Investing with The Juice!]( - [Big Money Name Their Top 5 Semiconductor Stocks for 2024]( - [Pros Pick Their Top 5 Online Advertising Stocks]( [News & Insights-facebook-share]( [News & Insights-twitter-share]( [News & Insights-linkedin-share]( [News & Insights-email-share](mailto:?body= %3Cbr+%2F%3E%0A%3Cb%3ENotice%3C%2Fb%3E%3A++Undefined+property%3A+stdClass%3A%3A%24previewText+in+%3Cb%3E%2Fvar%2Fwww%2Fhtml%2Fnl_forms%2Fsrc%2FICTheSpill%2Fautomate-ic-article.php%3C%2Fb%3E+on+line+%3Cb%3E102%3C%2Fb%3E%3Cbr+%2F%3E%0Ahttps%3A%2F%2Finvestingchannel.com%2F%3Fp%3D607748?utm_medium=ic-nl&utm_source=116469 ) [We want to hear from you. Let us know your thoughts by clicking here]( [Ads] [InvestingChannel Logo](#) Follow us on: [Facebook Logo]( [LinkedIn Logo]( [Twitter Logo]( [Instagram Logo]( To ensure delivery of all emails, [allow us on your list](. Manage your subscriptions with our [preference center](. [Unsubscribe here.]( View our privacy policy [here](. Copyright ©2024 InvestingChannel. All rights reserved. 1325 Avenue of the Americas, Floor 27 & 28 New York, New York 10019 Disclaimer: This is not investment advice. This InvestingChannel, Inc., newsletter is for information purposes only and is based on opinion. Futures, forex, stock, and options trading are not appropriate for all investors. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or eliminate losses. InvestingChannel, Inc., makes no representation or implication that using any of the methodologies or systems in this newsletter will generate returns or insure against losses. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions. [Link](